Prof Tony Mok speaks to ecancer about the long-term follow-up from the phase 3 CROWN trial. It shows that lorlatinib continues to provide exceptional and durable benefit in patients with treatment-naïve advanced ALK-positive non-small cell lung cancer.

After 7 years of follow-up, median progression-free survival remains unreached with lorlatinib, with more than half of patients progression-free at 7 years compared to just 3% with crizotinib.

Patients who remained progression-free at 2 years had a 79% chance of ongoing disease control at 7 years.

Notably, lorlatinib demonstrated sustained intracranial protection, with no new brain progression events after 30 months. The safety profile remained consistent over time, with manageable adverse events and low discontinuation rates.

These results reinforce lorlatinib as a highly effective first-line therapy in ALK+ NSCLC, offering long-term disease control and meaningful improvements in patient outcomes.